Fulcrum Therapeutics Inc.(FULC)

$3.84▲0.20 (5.49%)

Chart

Fulcrum Therapeutics Inc.(FULC)

NASDAQ

$3.84▲0.20 (5.49%)

Chart Studio

FULC(FULC)

FULC

Overview Notebook Intelligence Chart History Fundmntls TTM Earnings Analysts News Financials Segments Insiders Institl.DCF Peers

Q3 2026 EPS Estimate

$-0.21

Aug 4, 2026 · Reports before open

FY2030E EPS$0.17

Analyst Sentiment

Wall St. Consensus

Hold

16 analysts·Moderate coverage

Score

7 Buy (44%)6 Hold (38%)3 Sell (18%)

Rating Breakdown

Strong Buy

00%

Buy

744%

Hold

638%

Sell

319%

Strong Sell

00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Bear

$3.00

-21.9%

Consensus

$4.00

+4.2%

Bull

$4.00

+4.2%

12-Month Target Range16 analysts

$3.00$4.00$4.00

Current $3.84Consensus

Current Price

$3.84

Upside to Consensus

$0.16

Price targets are 12-month analyst forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

Forward Growth Estimates (YoY)

FY2027

Rev+115722.89%

EPS—

FY2028

Rev-84.92%

EPS—

FY2029

Rev+115.66%

EPS—

Raw consensus estimates (low / average / high) from covering analysts.

Annual

Metric	FY2026E	FY2027E	FY2028E	FY2029E	FY2030E
Revenue Avg	$311,890	$361M	$54M	$117M	$203M
Low	$311,890	$361M	$54M	$117M	$203M
High	$311,890	$361M	$54M	$117M	$203M
EBITDA Avg	$-138,978	$-161M	$-24M	$-52M	$-91M
Low	$-138,978	$-161M	$-24M	$-52M	$-91M
High	$-138,978	$-161M	$-24M	$-52M	$-91M
EBIT Avg	$-140,221	$-162M	$-24M	$-53M	$-91M
Low	$-140,221	$-162M	$-24M	$-53M	$-91M
High	$-140,221	$-162M	$-24M	$-53M	$-91M
Net Income Avg	$-63M	$-53M	$-55M	$-20M	$11M
Low	$-77M	$-109M	$-104M	$-20M	$11M
High	$-26M	$-1M	$-600,292	$-20M	$11M
EPS Avg	$-0.78	$-0.67	$-0.65	$-0.32	$0.17
Low	$-1.21	$-1.73	$-1.65	$-0.32	$0.17
High	$-0.41	$-0.02	$-0.01	$-0.32	$0.17
Analysts (Rev / EPS)	7 / 7	8 / 7	5 / 5	2 / 1	2 / 1

Quarterly

Metric	Q3 2026	Q4 2026	Q1 2027	Q2 2027	Q3 2027	Q4 2027
Revenue Avg	—	—	—	—	—	—
Low	—	—	—	—	—	—
High	—	—	—	—	—	—
EBITDA Avg	—	—	—	—	—	—
Low	—	—	—	—	—	—
High	—	—	—	—	—	—
EBIT Avg	—	—	—	—	—	—
Low	—	—	—	—	—	—
High	—	—	—	—	—	—
Net Income Avg	$-12M	$-13M	$-22M	$-22M	$-23M	$-23M
Low	$-20M	$-13M	$-22M	$-22M	$-23M	$-23M
High	$-5M	$-13M	$-22M	$-22M	$-23M	$-23M
EPS Avg	$-0.16	$-0.16	$-0.29	$-0.29	$-0.30	$-0.30
Low	$-0.26	$-0.16	$-0.29	$-0.29	$-0.30	$-0.30
High	$-0.07	$-0.16	$-0.29	$-0.29	$-0.30	$-0.30
Analysts (Rev / EPS)	— / 5	— / 1	— / 1	— / 1	— / 1	— / 1

Earnings Surprises

Recent Analyst Actions

Jun 2, 2026H.C. Wainwright

Fulcrum Therapeutics downgraded to Neutral from Buy at H.C. Wainwright

Target:$3.00

-53.3%from $6.42

Jun 2, 2026Jefferies

Leerink Downgrades Fulcrum Therapeutics (FULC) to Market Perform

Target:$4.00

-37.7%from $6.42

Jun 2, 2026Leerink Partners

Fulcrum Therapeutics downgraded to Market Perform from Outperform at Leerink

Target:$4.00

-37.7%from $6.42

Jun 2, 2026Truist Financial

Truist Securities Downgrades Fulcrum Therapeutics (FULC) to Hold

Target:$4.00

-37.7%from $6.42

Jun 2, 2026Piper Sandler

Fulcrum Therapeutics downgraded to Underweight from Overweight at Piper Sandler

Target:$3.00

-53.3%from $6.42

Feb 24, 2026Truist Financial

Fulcrum Therapeutics price target lowered to $17 from $18 at Truist

Target:$17.00

+89.8%from $8.96

Dec 11, 2025Truist Financial

Fulcrum Therapeutics price target raised to $18 from $14 at Truist

Target:$18.00

+42.3%from $12.64

Dec 8, 2025Stifel Nicolaus

Fulcrum Therapeutics price target raised to $25 from $20 at Stifel

Target:$25.00

+77.7%from $14.07

Dec 8, 2025Cantor Fitzgerald

Fulcrum Therapeutics price target raised to $24 from $15 at Cantor Fitzgerald

Target:$24.00

+74.7%from $13.74

Dec 8, 2025RBC Capital

Fulcrum Therapeutics price target raised to $10 from $7 at RBC Capital

Target:$10.00

-28.9%from $14.06

Dec 8, 2025Piper Sandler

Fulcrum Therapeutics price target raised to $23 from $16 at Piper Sandler

Target:$23.00

+158.4%from $8.90

Dec 8, 2025H.C. Wainwright

Fulcrum Therapeutics price target raised to $25 from $18 at H.C. Wainwright

Target:$25.00

+180.9%from $8.90

Nov 24, 2025Truist Financial

Fulcrum Therapeutics initiated with a Buy at Truist

Target:$14.00

+24.0%from $11.29

Nov 24, 2025H.C. Wainwright

Fulcrum Therapeutics (FULC) PT Raised to $18 at H.C. Wainwright

Target:$18.00

+59.4%from $11.29

Oct 30, 2025Piper Sandler

Fulcrum Therapeutics price target raised to $16 from $12.50 at Piper Sandler

Target:$16.00

+70.9%from $9.36

Oct 21, 2025Leerink Partners

Fulcrum Therapeutics (FULC) PT Raised to $20 at Leerink Partners

Target:$20.00

+116.9%from $9.22

Jul 29, 2025H.C. Wainwright

H.C. Wainwright upgrades Fulcrum to Buy on sickle cell data

Target:$12.00

+58.1%from $7.59

May 29, 2025Piper Sandler

Fulcrum Therapeutics price target raised to $9 from $6 at Piper Sandler

Target:$9.00

+27.0%from $7.08

May 23, 2025Leerink Partners

Fulcrum Therapeutics upgraded to Outperform from Market Perform at Leerink

Target:$12.00

+86.3%from $6.44

Sep 13, 2024H.C. Wainwright

Fulcrum Therapeutics downgraded to Neutral from Buy at H.C. Wainwright

Target:$4.00

+16.3%from $3.44

Sep 12, 2024RBC Capital

Fulcrum Therapeutics downgraded to Sector Perform from Outperform at RBC Capital

Target:$4.00

+16.3%from $3.44

Sep 12, 2024Stifel Nicolaus

Fulcrum Therapeutics downgraded to Hold from Buy at Stifel

Target:$3.00

-15.6%from $3.55

Sep 12, 2024Bank of America Securities

BofA Securities Downgrades Fulcrum Therapeutics (FULC) to Underperform

Target:$2.00

-41.9%from $3.44

Sep 9, 2024Bank of America Securities

BofA Securities Upgrades Fulcrum Therapeutics (FULC) to Neutral

Target:$10.00

+16.2%from $8.61

Sep 3, 2024RBC Capital

Fulcrum Therapeutics (FULC) PT Raised to $15 at RBC Capital

Target:$15.00

+79.1%from $8.37

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance